Mobocertinib

(Exkivity®)

Mobocertinib

Drug updated on 11/15/2023

Dosage FormCapsule (oral; 40 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Exkivity (mobocertinib) Prescribing Information.2023Takeda Pharmaceuticals America Inc., Lexington, MA

Systematic Reviews / Meta-Analyses